The Novavax COVID-19 vaccine, codenamed
NVX-CoV2373, and also called SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI) and is undergoing trials in India under the brand name Covovax.
It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) (refrigerated).
NVX-CoV2373 has been described as both a protein subunit vaccine and a virus-like particle vaccine,though the producers call it a "recombinant nanoparticle vaccine".
The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The spike protein was modified by incorporating two proline amino acids in order to stabilize the pre-fusion form of the protein; this same 2P modification is being used in several other COVID-19 vaccines. The baculovirus then infects a culture of Sf9 moth cells, which create the spike protein and display it on their cell membranes. The spike proteins are then harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.
The formulation includes a saponin-based adjuvant.
So if I’m reading this right… the spike protein used to train the immune system is created in the lab?
That’s good - though there’s still the issue that it’s the spike proteins themselves (made inside the body or not) that are the issue causing the heart attacks.
So this is not an mRNA shot?
It is spike proteins mashed onto moth cells?
Our bodies learn from spikes that do not enter cells or inject DNA or RNA?
Ool! I wanna be Mothra!
